Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis-Reference-Cited by-同舟云学术

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

Published:2003-07-09 Issue:2 Volume:290 Page:238
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Abraham Edward,Reinhart Konrad,Opal Steven,Demeyer Ignace,Doig Christopher,Rodriguez Angel López,Beale Richard,Svoboda Petr,Laterre Pierre Francois,Simon Stuart,Light Bruce,Spapen Herbert,Stone Judy,Seibert Allan,Peckelsen Claus,De Deyne Cathy,Postier Russell,Pettilä Ville,Sprung Charles L.,Artigas Antonio,Percell Sandra R.,Shu Vincent,Zwingelstein Christian,Tobias Jeffrey,Poole Lona,Stolzenbach James C.,Creasey Abla A.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 853 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis;Intensive Care Medicine;2024-09-02

2. Efficacy of unfractionated heparin in patients with moderate sepsis-induced coagulopathy: An observational study;Thrombosis Research;2024-09

3. Heparin Therapy and Mortality in Patients with Sepsis: An Observational Study Using a Marginal Structural Cox Model Based on MIMIC-IV Database;Intensive Care Research;2024-06-25

4. Associations of tissue factor and tissue factor pathway inhibitor with organ dysfunctions in septic shock;Scientific Reports;2024-06-24

5. Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice;Journal of Thrombosis and Haemostasis;2024-06